Three Neurocognitive Profiles Identified for Children Born Prematurely
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 19, 2024 -- Children born prematurely can be categorized into three distinct neurocognitive profiles, according to a study published online Aug. 13 in Child Development.
Iris Menu, Ph.D., from NYU Langone Health in New York City, and colleagues applied a latent profile analysis to the National Institutes of Health Toolbox performance of 1,891 healthy prematurely born children from the Adolescent Brain and Cognitive Development study to identify developmental trajectories.
The researchers identified three distinct neurocognitive profiles: (1) consistently performing above the norm; (2) mixed scores; and (3) consistently performing below the norm (19.7, 41.0, and 39.3 percent, respectively). Lasting cognitive, neural, behavioral, and academic differences were seen in association with these profiles.
"Based on these results, we call for the launch of social and structural interventions that ensure all preterm-born children receive equitable care," Menu said in a statement. "Children that get speech, physical, and behavioral therapy almost every day, which is more likely to happen in affluent households, tend to do better on the study tests, but there are other factors involved. For instance, children in communities where more are covered by health insurance were less likely to belong to profile 3."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-20 03:15
Read more
- ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
- Diabetes & Kidney Trouble Can Bring Heart Disease Decades Earlier
- Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
- Different Forms of Childhood Adversity Tied to Different Psychiatric Problems
- New Hope Against a Rare, Aggressive Form of Thyroid Cancer
- UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions